Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Pharmacol Ther ; 97(3): 234-46, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25669457

ABSTRACT

The concept of adaptive licensing (AL) has met with considerable interest. Yet some remain skeptical about its feasibility. Others argue that the focus and name of AL should be broadened. Against this background of ongoing debate, we examine the environmental changes that will likely make adaptive pathways the preferred approach in the future. The key drivers include: growing patient demand for timely access to promising therapies, emerging science leading to fragmentation of treatment populations, rising payer influence on product accessibility, and pressure on pharma/investors to ensure sustainability of drug development. We also discuss a number of environmental changes that will enable an adaptive paradigm. A life-span approach to bringing innovation to patients is expected to help address the perceived access vs. evidence trade-off, help de-risk drug development, and lead to better outcomes for patients.


Subject(s)
Drug Approval/legislation & jurisprudence , Drug Approval/methods , Drug Discovery/legislation & jurisprudence , Licensure , Humans
2.
Nutr Metab Cardiovasc Dis ; 24(12): 1346-53, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25300980

ABSTRACT

BACKGROUND AND AIMS: In Italy, the reimbursed use of incretin mimetics and incretin enhancers was subject to enrollment of patients into a web-based system recording the general demographic and clinical data of patients. We report the utilization data of glucagon-like peptide 1 (GLP1) receptor agonists and dipeptidylpeptidase-4 (DPP4) inhibitors in clinical practice as recorded by the Italian Medicines Agency (AIFA) Monitoring Registry. METHODS AND RESULTS: From February 2008 to August 2010, 75,283 patients with type 2 diabetes were entered into the registry and treated with exenatide, sitagliptin, or vildagliptin. The treatment was administered to patients in a wide range of ages (≥75 years, n = 6125 cases), body mass index (BMI) (≥35 kg/m(2), n = 22,015), and metabolic control (HbA(1c) ≥ 11% ((96 mmol/mol), n = 3151). Overall, 1116 suspected adverse drug reactions were registered, including 12 cases of acute pancreatitis (six on exenatide). Hypoglycemic episodes mainly occurred in combination with sulfonylureas. Treatment discontinuation for the three drugs (logistic regression analysis) was negatively associated with the male gender and positively with baseline HbA1c, diabetes duration, and, limitedly to DPP-4 inhibitors, with BMI. Treatment discontinuation (including loss to follow-up, accounting for 21-26%) was frequent. Discontinuation for treatment failure occurred in 7.7% of cases (exenatide), 3.8% (sitagliptin), and 4.1% (vildagliptin), respectively, corresponding to 27-40% of all discontinuations, after excluding lost to follow-up. HbA1c decreased on average by 0.9-1.0% (9 mmol/mol). Body weight decreased by 3.5% with exenatide and by 1.0-1.5% with DPP-4 inhibitors. CONCLUSIONS: In the real world of Italian diabetes centers, prescriptions of incretins have been made in many cases outside the regulatory limits. Nevertheless, when appropriately utilized, incretins may grant results at least in line with pivotal trials.


Subject(s)
Adamantane/analogs & derivatives , Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/therapeutic use , Nitriles/therapeutic use , Peptides/therapeutic use , Pyrazines/therapeutic use , Pyrrolidines/therapeutic use , Triazoles/therapeutic use , Venoms/therapeutic use , Adamantane/administration & dosage , Adamantane/adverse effects , Adamantane/therapeutic use , Aged , Blood Glucose/metabolism , Body Weight , Diabetes Mellitus, Type 2/epidemiology , Drug Utilization , Drug-Related Side Effects and Adverse Reactions , Exenatide , Female , Glycated Hemoglobin/analysis , Humans , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/adverse effects , Italy/epidemiology , Male , Metformin/therapeutic use , Middle Aged , Monitoring, Physiologic , Nitriles/administration & dosage , Nitriles/adverse effects , Peptides/administration & dosage , Peptides/adverse effects , Pyrazines/administration & dosage , Pyrazines/adverse effects , Pyrrolidines/administration & dosage , Pyrrolidines/adverse effects , Registries , Sex Factors , Sitagliptin Phosphate , Triazoles/administration & dosage , Triazoles/adverse effects , Venoms/administration & dosage , Venoms/adverse effects , Vildagliptin
3.
Ann Oncol ; 21(10): 2081-2087, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20335370

ABSTRACT

AIM: The main purpose of this study was to identify each sequential phase followed by an oncology product, from European assessment until to patient access in each Italian region (IR). METHODS: A panel of oncology products approved by the European Medicines Agency (EMA) in the period 2006-2008 was considered. The explored sequential phases included the times to market for: the EMA; pharmaceutical companies; the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA); and IRs as final providers of health care. The IR's time to market was also analyzed by a Cox regression model. RESULTS: The overall mean time required before patients access was 2.3 years. EMA accounted for the greater proportion of time (31.8%), followed by AIFA (28.2%). However, the duration for both pharmaceutical companies and IRs was associated with the highest variability. An oncology product authorized with a risk-sharing agreement showed an early access in the IRs. On the contrary, the introduction in IRs having a compulsory formulary was delayed. Both a high forecast of economic impact and a high oncology product price can also delay the patient access. CONCLUSION: The process before patient access to an oncology product is time and cost consuming. This study identifies the main predictors that affect the missing overlap between market and patient access in Italy.


Subject(s)
Antineoplastic Agents/economics , Antineoplastic Agents/supply & distribution , Drug Utilization , Health Personnel , Health Services Accessibility , Marketing/economics , Europe , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...